RNA sequencing (RNA-Seq) is a powerful method for studying the transcriptome qualitatively and quantitatively. It can identify the full catalog of transcripts, precisely define the structure of genes, and accurately measure gene expression levels.
GENEWIZTM RNA sequencing services from Azenta provide unparalleled flexibility in the analysis of different RNA species (coding, non-coding, and small transcripts) from a wide range of starting material using long- or short-read sequencing. Our US-based processing and support provides the fastest and most reliable service for North American customers.
Single-cell RNA sequencing analyzes gene expression at single-cell resolution for heterogeneous samples. The 10x Genomics® Chromium™ platform provides advanced transcriptional profiling of thousands of individual cells.
Ultra-low input RNA sequencing provides bulk expression analysis of samples containing as few as 10 pg of RNA or just a few cells. Recommended for sequencing cells after fluorescence-activated cell sorting (FACS) or immunoprecipitation (RIP-Seq).
Standard RNA sequencing is our most popular option for profiling gene expression, enabling the analysis of coding (mRNA) and long non-coding RNA (lncRNA).
Strand-specific RNA sequencing provides gene expression information with relation to strand orientation. Used for genome annotation, analysis of anti-sense/overlapping transcripts, and novel transcript discovery.
RNA-Seq services performed in a CAP/CLIA laboratory for clinical applications. Custom CLIA validations for specific assays.
Find the right NGS solution for your project using our interactive guide.
Poly(A) tail sequences can impact the integrity of your mRNA plasmids for in vitro transcription. While longer poly(A) tails have been shown to increase their stability, tails greater than 100 bases are susceptible to truncations. Learn how the proprietary mRNA plasmid preparation protocol from Azenta can help you generate higher yields and preserve poly(A) tails of greater lengths compared to standard protocols for high-fidelity templates in our tech note.
Strict quality control is required to maintain the integrity of manufactured products for RNA therapies, but current assays often present limitations. Learn how the novel full-length RNA-Seq approach from Azenta allows you to preserve the entire length of and effectively sequence the poly(A) tails of your mRNA products.
For those new to bioinformatics, analyzing massive amounts of NGS data can be a daunting task. Download Azenta’s bioinformatics quick start guide to learn how to analyze whole genome sequencing (WGS) and RNA sequencing (RNA-Seq) data with bioinformatics tools to reveal biological insights for your research.
Developing immunotherapies for cancer can be difficult due to the variation of immune response from patient to patient. In this webinar, Dr. Litchfield from UCL Cancer Institute presents his team’s exploratory research using a multiomics approach to better understand the diversity of immune response to cancer and highlights their findings of an alternative source of a tumour-specific antigen in checkpoint inhibitor (CPI) response.
With this two-part webinar series, go beyond traditional transcriptomics and learn about the various NGS approaches available for gene expression analysis. In part 1, we take an in-depth look at various gene expression approaches, including RNA-Seq, single-cell RNA-Seq, digital spatial profiling, and more. In part 2, we explore the data generated from these approaches and how they can complement each other and confirm findings.
RNA-Seq bioinformatics can be complex and difficult to decipher. To help make it more approachable, this workshop and roundtable discussion, led by Azenta Life Sciences' bioinformatics manager Brian Sereni, explores the bioinformatics pipeline, explains NGS results, and addresses common challenges and FAQs for RNA-Seq bioinformatics analysis.
Obtaining samples with high cell viability can be difficult for many experiments but is necessary for success on the 10x Genomics® Chromium™ platform. This tech note describes how Azenta scientists used optimized single-cell workflows, including dead cell removal, to overcome low viability and generate high-quality sequencing data.
Biomedical specimens are often restricted to minute quantities, posing major limitations to RNA-Seq. This case study shows how approximately 50 sorted cells from a glioblastoma can produce transcriptomic data comparable to RNA-Seq experiments that use millions of cells.
Cell populations are rarely homogeneous and synchronized in their characteristics. Standard RNA-Seq approaches are limited to reporting general expression levels thus omitting minor subpopulation profiles. This study highlights new single-cell RNA sequencing capabilities for identifying rare cells, characterizing their transcriptomes, and discovering potential biomarkers.
Contiguous mRNA full-length sequencing (Iso-Seq) greatly simplifies genome annotation efforts and revolutionizes the discovery of novel RNA isoforms. This Tech Note discusses the advantages of the latest technologies combined with Azenta’s optimized workflow, and how this increases output and accuracy.
In comparison to traditional profiling methods which assess bulk populations, single-cell technologies empower researchers to examine diversity of heterogeneous cell populations and uncover new, and potentially unexpected, biological discoveries. This webinar highlights the unparalleled capabilities of single-cell sequencing.
High-throughput technologies are critical in performing phenotypic profiling for drug discovery applications. In this tech note, Azenta Life Sciences discusses the challenges associated with traditional approaches, such as microarrays and RNA sequencing, and offers an optimized assay to achieve high-quality phenotypic profiling at a reduced cost for rapid drug discovery.
This selection guide offers practical information about PCR + Sanger, qPCR, and NGS approaches to help you determine which assay best suits your project requirements, along with an interactive assay selection tool to aid your decision making.
The structure of mRNA has been known for decades, but only in recent years have researchers unlocked its potential for therapeutic development. With the right delivery vehicle, mRNA products can replace defective proteins in the cell, generate antigens for immunization (e.g., COVID vaccines), or edit the genome via CRISPR technology. Let’s review the structural features of a functional mRNA molecule and discuss how to optimize these for therapeutic applications.
10X GENOMICS® CHROMIUM™